|
Journal of Indian Association of Pediatric Surgeons, Vol. 10, No. 4, October-December, 2005, pp. 217-228 Review Articles Saga of Wilms' tumor: Lessons learnt from the past Gupta DevendraK, Sharma Shilpa, Agarwala Sandeep, Carachi* Robert Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi and *Yorkhill's Children's Hospital, Glasgow, U.K. Code Number: ip05054 Abstract Wilms' tumor (WT) represents 6% of childhood cancers. Recent advances in molecular biology have significant implications for the clinical management. A dramatic improvement in overall cure has resulted from the adoption of multimodality treatment during the past few decades. National Wilms' Tumor Study (NWTS), and the Société Internationale d'Oncologie Pédiatrique (SIOP) have laid down the guidelines for standardized treatment of WT, though differing in the diagnostic and therapeutic approach. Both these groups currently aim at intensifying treatment for patients with poor prognosticators while appropriating the therapy to reduce long-term complications for those with favorable prognostic features. Challenges faced in developing nations include poverty, malnutrition, ignorance, and presentation in advanced stages coupled with limited facilities that are necessary for total management of these cases. In this article, we have discussed our approach to deal with patients with nephroblastoma, reviewed the literature on the current management strategies and the long-term outcome. Most countries have adopted the NWTS protocols, while others especially in Europe, South America and some Asian countries follow the SIOP regimen. Both have their advantages and weaknesses and maynot necessarily be suitable to the setup in developing countries. We have discussed the controversial issues in the management of WT including the timing of biopsy, type of biopsy, investigative approach, role of chemotherapy / radiotherapy, management of bilateral Wilms' tumor and parenchymal sparing renal surgery. Despite deviating from NWTS at various points, the overall results have remained satisfactory. Thus, developing countries might adopt their own protocols depending on the prevalent situations and facilities available to them to treat such patients.Keywords: Wilms′ tumor, Nephroblastoma, NWTS, Pediatric malignancy Wilms′ tumor was first described by Thomas F. Rance in 1814. However, Max Wilms, a German surgeon and pathologist, gave the detailed description, adding seven new patients of his own in 1899 and since then the tumor bears his name.[1] Wilms′ tumor (nephroblastoma) is an embryonic kidney tumor. It is the most common abdominal tumor in children and represents 6% of childhood cancer. Wilms′tumor is primarily a disease of the kidney, but occasionally extrarenal locations have been reported, especially in the retroperitoneum, the sacrococcygeal region, testis, uterus, inguinal canal, and mediastinum.[2] A dramatic improvement in overall survival rates lately has resulted from the coordinated use of modern surgical technique and anaesthesia, multiple drug chemotherapy, and radiation therapy.[3] Large cooperative cancer groups, especially the National Wilms′ Tumor Study (NWTS), and the Société Internationale d′Oncologie Pédiatrique (SIOP) have laid down guidelines for standardized treatment of this tumor and thus achieved a 5-year survival rate of more than 90%. The median age at diagnosis is 41.5 months for males with unilateral tumor and 46.9 months for females with unilateral tumors.[4] For bilateral tumors the median age at presentation is 29.5 months for males and 32.6 months for females.[4] The male to female ratio is 0.92 for unilateral tumors and 0.6 for bilateral tumors. Most of the patients present before 5 years of age. Wilms′ tumor is bilateral at presentation in 4% to 8% of cases. Associated anomalies Wilms′ tumor is associated with congenital anomalies in 10% to 13% of cases. Aniridia is present in 10% of children; hemihypertrophy is noted in 2% to 3%. Other genitourinary malformations are present is 5% of cases mainly cryptorchidism, hypospadias, double collecting system or fused kidney. Rarely, Wilms′ tumor has been found in a horseshoe kidney.[5] Congenital abnormalities are seen more commonly is bilateral tumors. The "Denys-Drash Syndrome" is a combination of Wilms′ tumor, male pseudohermaphroditism and glomerulonephritis. The "WAGR Syndrome" is a combination of WT with aniridia, genitourinary malformations and mental retardation. Wilms′ tumor also occurs with increased frequency in the "Beckwith - Wiedemann syndrome" which includes macrosomia, hemihypertrophy, and macroglossia. Hemihypertrophy is extremely rare and normally seen in only 3 per 100,000 children. Other associated malformations include Septal defects, microcephalus, hyperinsulinism, and von Willebrand′s disease (8%).Molecular Biology Nephrogenic rests, potentially premalignant lesions, are found in the kidneys of 30 to 40% of children with Wilms′tumors.[6] In 1984, the loss of heterozygosity (LOH) on chromosome 11p alleles was described in up to 40% of Wilms′ tumors. A "two hit model" similar to that of retinoblastoma was proposed, indicating a recessive mutation in the etiology of Wilms′tumor. Wilms′ tumor (hereditary or sporadic) appears to result from changes in one or more of several genes. Specific germ-line mutations in one of these genes (Wilms′ tumor gene-1, WT1) located on the short arm of chromosome 11 (band 11p13) are not only associated with Wilms′ tumor but also cause a variety of genitourinary abnormalities such as cryptorchidism and hypospadias, and the rare Denys-Drash syndrome. A gene that causes aniridia is located near the WT1 gene on chromosome 11p13, and deletions encompassing the WT1 and aniridia genes may explain the association between aniridia and Wilms′ tumor. Patients with aniridia or hemihypertrophy should be screened with ultrasound every 3 months until they are 6 years of age. There appears to be a second Wilms′ tumor gene (WT 2) at or near the Beckwith-Wiedemann gene locus on chromosome 11p15, and children with Beckwith-Wiedemann syndrome are at increased risk for developing Wilms′ tumor. Approximately one-fifth of patients with Beckwith-Wiedemann syndrome who develop Wilms′tumor present with bilateral disease, primarily at diagnosis, although metachronous recurrence is also observed. The presence of structural anomalies of chromosome 17 in approximately 15% of tumors and the observation of an individual with Wilms′tumor in a Li-Fraumeni family (a cancer susceptibility syndrome with germ line mutations of p53) suggested a role for the p53 tumor suppressor gene.[7] The p53-encoded protein appears to act as a cell cycle checkpoint protein that arrests cell growth in G1. Inactivation by mutation or alteration results in genomic instability and cytogenetic aberrations (e.g. aneuploidy, translocations, deletions, and gene amplification).[8] Genes on other chromosomes may also have an etiologic role in Wilms′ tumor, and loss of genetic material from chromosome 16 and/or chromosome 1p occurs in some tumors. Many Wilms′tumors appear to arise from abnormally retained embryonic kidney precursor cells arranged in clusters termed nephrogenic rests. The different genetic lesions are associated with different subtypes of nephrogenic rests. DNA content Some studies suggested that flow cytometric evaluation of DNA-ploidy is a useful predictor of outcome and response to therapy. Diploid and aneuploid tumors are reported to have better long-term survival when compared with tetraploid tumors. However, other studies reported that this factor is not superior compared to histology and staging. Ongoing studies will determine the clinical usefulness of DNA-ploidyHereditary Factors Despite the number of genes that appear to be involved in the development of Wilms′ tumor, hereditary Wilms′ tumor (either bilateral tumors or a family history of the neoplasm) is uncommon, 1% to 2% of patients having a positive family history for Wilms′ tumor. The risk of Wilms′ tumor among offspring of persons who have had unilateral (i.e., sporadic) tumors is quite low (<2%). Siblings of children with Wilms′ tumor have a low likelihood of developing Wilms′ tumor. A second Wilms′ tumor may develop in the remaining kidney of 1% to 3% of children treated successfully for Wilms′ tumor. The incidence of such metachronous bilateral Wilms′ tumors is much higher in children whose original Wilms′ tumor was diagnosed at less than 12 months of age and/or whose resected kidney contains nephrogenic rests. Periodic abdominal ultrasound is recommended for early detection of metachronous bilateral Wilms′ tumor as follows: children with nephrogenic rests in the resected kidney (if < 48 months of age at initial diagnosis) - every 3 months for 6 years; children with nephrogenic rests in the resected kidney (if > 48 months of age at initial diagnosis) - every 3 months for 4 years; other patients - every 6 months for 2 years, then yearly for an additional 1 to 3 years. Clear cell sarcoma of the kidney and rhabdoid tumor of the kidney are childhood renal tumors unrelated to Wilms′ tumor. Because of their renal location, they have been treated on clinical trials developed by the National Wilms′ Tumor Study Group. The approach to their treatment, however, is distinctive from that of Wilms′tumor, and requires timely and accurate diagnosis. Clinical Presentation Patients usually present with a large, smooth and non-tender flank mass on palpation, usually noted by a parent. About a quarter may have associated (microscopic) hematuria, dysuria, malaise, weight loss, anemia, or hypertension. The tumor can rupture with trivial trauma and these patients present with acute abdominal pain. Obstruction of the left spermatic vein by the mass can result in a left-sided varicocele. Few cases of Wilms′ tumor have been diagnosed antenatally with help of ultrasonography.[9] It is usually associated with polyhydramnios. Increased mortality has been reported if associated with fetal hydrops.[10] Laboratory Tests Recently, urinary basic Fibroblast Growth Factor (bFGF) has been reported to be elevated preoperatively in patients with Wilms′ tumor.[11] Rebhandl et al. described the Tissue Polypeptide Specific antigen (TPS), a cytokeratin-18 derived marker, which might be of clinical value in monitoring the therapy of nephroblastoma.[12] Hypertension may be associated with Wilms′ tumor. Increased plasma prorenin and renin levels, found by several investigators, could be the cause. The serum level of neuron-specific enolase (NSE) and urinary catecholamine levels should be routinely measured to exclude neuroblastoma.Imaging Studies Advances in radiological techniques are able to detect non-palpable Wilms′tumors, nephroblastomatosis, and tumor spread much earlier and in a less invasive manner than in the past. An abdominal ultrasound study of the mass and color-duplex investigation of the renal vessels should be performed. Thus, the extent of renal involvement (contralateral kidney), the renal vein, the inferior vena cava (IVC) and the liver can be assessed. Additionally, high-resolution sonography may detect areas of nephroblastomatosis usually presenting as multiple solid, subcapsular, hypovascular and hypoechogenic nodules or cysts. Skiagram chest, CT scans of the chest and the abdomen should also be done as baseline diagnostic procedures for complete evaluation of the extent of the mass. Following the NWTS-5 recommendations, positive findings seen in chest CT but not on chest radiograph should be ignored.[13] Whether the accuracy of CT or MRI obviates the need for surgical exploration of the contralateral kidney remains controversial. MRI studies have a predominant role in demonstrating the relation of the tumor to other organs. MRI, along with ultrasound is more sensitive than CT for assessing extension of a tumor thrombus into the inferior vena cava (IVC) with the additional possibility of MR-venography. Nephrogenic rests (NRs) as small as 4mm typically appear as homogeneous lesions after Gadolinium enhancement, different from the heterogeneous appearance of Wilms′tumor. SIOP-investigators strongly recommend a judgement by a reference radiologist because in these studies preoperative chemotherapy without histopathological diagnosis is favored. If there is no clear discrimination from neuroblastoma, an I (131) metaiodobenzylguanidine (MIBG)-scan may be performed. Patients with clear cell sarcoma or rhabdoid tumor of the kidney additionally need skeletal radiographs, radionuclide bone scans, and MRIs of the cranium. NWTS Classification of Pediatric Renal Tumors Low riskMesoblastic Nephroma Intermediate risk Favorable histology WT - Classic form of WT High risk Anaplastic Wilms′ tumor - focal - diffuse Clear cell sarcoma Rhabdoid tumor Prognostic Factors 1. Stage of the disease2. Favorable or unfavorable histology 3. Metastases at presentation 4. Regional lymph node involvement 5. Hyper-diploidy which correlates well with anaplastic variety NWTS Staging NWTS has pioneered the stage grouping of WT. Stage I Stage II Stage III Stage IV Stage V Histopathology Although most patients with a histologic diagnosis of Wilms′ tumor fare well with current treatment, approximately 12% of patients have histopathologic features that are associated with a poorer prognosis, and, in some types, with a high incidence of relapse and death. Wilms′tumor can be separated into two prognostic groups on the basis of histopathology: Favorable histology Unfavorable histology There are three main cytopathologic features of anaplasia: a) a threefold or greater nuclear enlargement, compared to the nearby nuclei of the same cell type e.g. stromal or epithelial; b) hyperchromatism (indicating that the nuclear enlargement is attributable to gross polyploidy and not to hydrophic swelling or poor fixation) and c) enlarged abnormal (usually multipolar) mitotic figures, which is regarded as the most quintessential criterion.[14] Nephrogenic rests (NR) According to their position within the lobe, the "perilobar (PLNR)" located at the periphery of the renal lobe are differentiated from the "intralobar (ILNR)" nephrogenic rests.[6] It is of interest that ILNR are consistently present in patients with deleted or mutated WT1-associated syndromes (WAGR complex - 11p13 locus, Denys-Drash syndrome), whereas PLNR are usually found in children with BWS (11p15 locus).[15] Management Multidisciplinary Treatment planning by a team of cancer specialists (pediatric surgeon or pediatric urologist, pediatric radiation oncologist, and pediatric oncologist) with experience in treating Wilms′tumor is required to determine and implement optimum treatment. Therapy consists of surgery followed by chemotherapy and, in some patients, radiation therapy. Operative principles have evolved from NWTS trials. The most important role for the surgeon is to ensure complete tumor removal without rupture and perform an assessment of the extent of disease. Radical nephrectomy via a transabdominal incision and lymph node sampling is the procedure of choice. The contralateral kidney must be palpated and inspected through an opening in the fascia. Hilar, peri-aortic, iliac and celiac lymph node sampling is mandatory. Furthermore, any suspicious node should be sampled. Margins of resection, residual tumor, and any suspicious node basins should be marked with titanium clips. Patients with massive, nonresectable unilateral tumors, bilateral tumors, or venacaval tumor thrombus above the hepatic veins are candidates for preoperative chemotherapy because of the risk of initial surgical resection. In the authors experience, Fine needle aspiration cytology (FNAC) has been practised routinely over decades without any untoward effects. The diagnostic accuracy in expert hands is high. Supplementation with immunocytochemistry helps to rule out other round cell tumors in cases with diagnostic dilemmas. A formal biopsy for histopathological confirmation, though practised by NWTS, is not recommended in cases appearing unresectable clinically. Pre-operative chemotherapy makes the tumor removal easier and may reduce the frequency of surgical complications. Newborns and all infants less than 12 months of age require a reduction in chemotherapy doses to 50% of those given to older children. This reduction diminishes toxic effects reported in children in this age group enrolled in NWTS studies while maintaining an excellent overall outcome. Liver function tests in children with Wilms′ tumor should be monitored closely during the early course of therapy based on hepatic toxic effects (veno-occlusive disease) reported in these patients. Dactinomycin should not be administered during radiation therapy. Children treated for Wilms′tumor are at increased risk for developing second malignant neoplasms. This risk depends on the intensity of their therapy, including the use of radiation and doxorubicin, and on possible genetic factors. Congestive heart failure has been shown to be a risk in children treated with doxorubicin. Efforts, therefore, have been aimed toward reducing the intensity of therapy where possible. The approach for treating clear cell sarcoma of the kidney is different from Wilms′ since the overall survival of children with CCSK remains considerably lower than patients with favorable histology Wilms′tumor. In the NSTS-3 study, the addition of doxorubicin to the combination of vincristine, dactinomycin, and radiation therapy resulted in an improvement in disease-free survival for patients with clear cell sarcoma of the kidney. Under the current NWTS study, children with stage II-IV diffuse anaplasia and stage I-IV clear cell sarcoma of the kidney are treated with a new chemotherapeutic regimen combining vincristine, doxorubicin, cyclophosphamide, and etoposide (Regime I) in an attempt to further improve the survival of these high-risk groups. All these patients will receive radiation therapy to the tumor bed. Patients with rhabdoid tumor of the kidney continued to have a poor prognosis on NWTS-4 regimens. In the study currently open, children with all stages of rhabdoid tumor of the kidney are being treated with carboplatin, cyclophosphamide, etoposide, and abdominal irradiation. Chemotherapy 2. Adjuvant chemotherapy
Regimen DD4A
Regimen I
Surgical Principles The incidence of post-operative complications in the NWTSG was 11%. The most serious complication intra-operatively is tumor embolus into pulmonary artery and sudden death. Common post-operative complications are Hemorrhage, Intestinal obstruction and Intestinal obstruction which in first post-op week is mostly due to intussusception and after that is due to adhesive obstruction. B. Role of contralateral exploration C. Intravascular tumor extension An infradiaphragmatic infrahepatic non-adherent caval vein thrombus generally can be removed by cavotomy or using a Fogarty or Foley balloon catheter. Patients with intravascular extension above the level of the hepatic veins should receive preoperative chemotherapy. Recent reports showed that preoperative therapy in patients with suprahepatic caval or atrial extension led to a marked decrease in size of tumor thrombus and even complete regression of thrombus without embolization. As an alternative in adverse cases, embolectomy under cardiopulmonary bypass is required. D. Parenchymal sparing surgery The
above procedures
can be done if following
criteria
are satisfied: Parenchymal sparing surgery is indicated
in Bilateral Wilms′Tumors The presence of synchronous bilateral disease requires alteration of management. It is not recommended to perform unilateral nephrectomy and contralateral biopsy or heminephrectomy as was the approach earlier. Initial unilateral nephrectomy may predispose patients with bilateral disease to late renal failure. Furthermore, studies demonstrate no difference in survival for children who undergo initial bilateral biopsy followed by chemotherapy and then surgical resection compared to those patients who had initial resection followed by chemotherapy. Surgical strategy therefore attempts to preserve renal mass to minimize the risk of late renal failure. The initial procedure is usually bilateral biopsies with lymph node sampling. Surgical stage should be assigned to both kidneys. Preoperative chemotherapy (vincristine and actinomycin-D in case of FH) may facilitate the subsequent second look. Following 6 weeks of chemotherapy the patient is reassessed. Approximately 10% of patients with bilateral tumors have unfavorable (anaplastic) histology and may benefit from more aggressive chemotherapy (addition of doxorubicin and cyclophosphamide) and radiation therapy and an aggressive surgical approach at the second-look operation. Salvage chemotherapy regimens using Cis-platinum, ifosfamide and VP-16 have been found to be helpful.[16] After chemotherapy, the patient is reassessed with abdominal CT to determine the feasibility of resection. If serial imaging studies show no further reduction in tumor, a second look surgical procedure should be performed. For small synchronous bilateral lesions at the poles, bilateral partial nephrectomies or wedge resections can be performed. Excisional biopsy or partial nephrectomy is regarded as appropriate only if radical tumor resection is not compromised, negative margins are obtained and if two thirds of the renal parenchyma can be preserved The goal is to achieve survival and at the same time to preserve an adequate amount of renal parenchyma. In case of a large tumor on one side and a contralateral small one, radical tumornephrectomy on the extensively involved site and partial nephrectomy on the opposite side is done. If conditions are not favorable for any surgical intervention, another biopsy is taken to confirm viable tumor. Chemotherapy and/or radiation therapy following the second-look operation is dependent on the response to initial therapy, with more aggressive therapy required for patients with inadequate response to initial therapy observed at the second procedure. A third look may be indicated; bilateral nephrectomy and subsequent renal transplantation remain the last issue. Unfortunately, due to immunosuppression, recurrence of disease occurs frequently. Before considering bilateral nephrectomy, bench surgery with autotransplantation and intraoperative radiotherapy may be performed. The cumulative survival rate for infants with bilateral tumors is approximately 65 to 70% at 10 years. However, one series reported overall survival of metachronous bilateral Wilms′ tumor to be 49.1% and 47.2% at 5 and 10 years, respectively.[17] Metachronous bilateral tumors were reported in about 1.5% of NWTS patients (58 of 4669 registered children). Since many of these lesions appear to be overlooked at initial laparotomy, a thorough investigation of the opposite kidney remains crucial. Children younger than 12 months diagnosed with Wilms tumors, who also have multicentric disease or NRs, in particular perilobar NRs, have a markedly increased risk of developing contralateral disease and require frequent and regular imaging of the contralateral kidney for several years. The median interval of diagnosis of metachronous Wilms′tumor ranges from 1.37 (NWTS) to 3.29 (SIOP) years.[17] Lung metastases Inoperable tumors Surgery is performed as soon as sufficient tumor shrinkage has occurred, generally within 6 weeks of diagnosis. Patients are subsequently treated as for stage III tumors, which includes postoperative radiation therapy. Because of the 5% to 10% error rate in preoperative diagnosis of renal masses after radiographic assessment, confirmation of the diagnosis by Fine needle aspiration cytology (FNAC) should be obtained prior to chemotherapy. Recurrent Wilms′Tumor Patients with anaplastic/unfavorable histology tumors, tumor recurrence in the abdomen after treatment with radiation therapy, recurrence within 6 months of nephrectomy, or recurrence after initial 3-drug therapy, have a poor prognosis. The risk factors associated with relapse in the authors series was unfavorable histology, lymph node involvement, age more than 6 years, diffuse spill, capsular and vascular invasion, and aneuploidy.[18] The 2-year survival rate for children after local recurrence is 43%. The combination of ifosfamide, etoposide and carboplatin has demonstrated efficacy in this group of patients, but significant hematologic toxic effects have been observed. While very high-dose chemotherapy followed by autologous bone marrow has been utilized in the past, a recent POG/CCG intergroup study used a salvage induction regimen of cyclophosphamide and etoposide (CE) alternating with carboplatin and etoposide (PE) followed by delayed surgery. Disease-free patients were assigned to maintenance chemotherapy with 5 cycles of alternating CE and PE, and the remainder of patients to ablative therapy and autologous marrow transplant. All patients received local radiation therapy. The 3-year survival was 52% for all eligible patients, while the 3-year survival was 64% and 42% for the chemotherapy consolidation and autologous marrow transplant subgroups, respectively. Patients in whom such salvage attempts fail should be offered treatment on available phase I or phase II studies. Radiotherapy The postoperative radiotherapy is started within 10 days of surgery because delay beyond 10 days leads to tumor cell repopulating aand increase in relapse rate. It has been shown that appropriate adjuvant RT reduces the postoperative recurrence to 0%-4% in children with favorable histology. The dose of radiotherapy has decreased to approximately 10 Gy from the doses of 25-30 Gy that were recommended in the past. Though radiotherapy has been recommended in bilateral Wilms′ tumor in reduced doses, the author advocates avoiding radiotherapy in Bilateral Wilms′ tumor and preferring salvaging chemotherapy schedules to prevent radiation nephritis and glomerulosclerosis. It has been seen by a long term evaluation of renal function in patients with irradiated bilateral Wilms tumor that 34.6% have deranged renal functions with elevated urea and creatinine levels.[19]
Partial nephrectomy Long-term complications Fortunately Wilms′ tumor is a curable malignancy in most patients, so limiting iatrogenic sequelae is essential wherever possible. Paulino et al. reported late effects of therapy in more than two thirds of children treated for Wilms′tumor.[22] Beside morbidity from chemotherapeutic agents, potential side effects of radiotherapy like intestinal strictures, ulceration, perforation, hematochezia, growth arrest and osteonecrosis have to be considered.[23]
1. Renal function 2. Lung damage 3. Congestive heart failure
4. Liver damage 5. Infertility 6. Second malignant neoplasms 7. Musculoskeletal function Prognosis At our institute the outcome of the 202 cases in last 17 years, the survival rate was 95% for stage I and II tumors, 75% for stage III tumors, 62% for stage IV tumors and 40% for stage V tumors. The number of cases stage-wise was stage I -19.3%, stage II -15.8%, stage III-43.0% stage IV -15.3% and stage V -6.4%. Contrary to the literature, we have seen bilateral WT, not only in much advanced stages but also in bulk, precluding residual effective renal parenchyma after surgical resection.[16]Follow up After completion of therapy, the frequency of imaging is dependent on the stage and histology of the tumor and physical and laboratory tests coincide with the schedule for imaging.[29] In general, all patients are reviewed every 3 months for the first year, and then every 6 months for another 2 years. During each of the follow-ups in the first three years it is recommended to get a radiological evaluation. This may be an ultrasound or CECT scan in addition to a chest x-ray. The likelihood of recurrence after the first three years is less, however these patients should be followed up every year for various long-term complications.Other pediatric renal tumors Clear Cell Sarcoma of the Kidney Bone metastases is the most common mode of relapse, followed by lung metastases, local (abdominal/retroperitoneal) recurrence, and brain metastases. It is of note that CCSK metastases were frequently encountered in unusual soft tissue (e.g. scalp, epidural, nasopharynx) and other sites (orbital). The time interval to relapse in the NWTS patient group ranged from <16 months to 4 years. Although the overall relapse rate is significantly lower for patients treated with doxorubicin, the risk of recurrence is prolonged. Currently (NWTS-5), patients with CCSK are treated with initial nephrectomy regardless of stage, abdominal radiation (10.8 Gy) and combined chemotherapy with actinomycin D, vincristine, and doxorubicin. The main prognosticators for favorable outcome in CCSK are revised stage 1, age at diagnosis (2-4 years), therapy with doxorubicin and absence of tumor necrosis.[30] Except for the presence of necrosis, which seems to be a feature of aggressive high-grade sarcomas, no other histopathologic pattern in CCSK appears to be of prognostic significance. Rhabdoid tumor Some of the patients have hypercalcemia. In about 15% of RTK, patients develop other primary embryonal tumors in the midline posterior fossa, particularly medulloblastoma. These intracranial tumors are histologically distinct from the primary renal lesion. In contrast to Wilms′ tumor, about 80% of RTKs have stage III or IV disease at presentation. Grossly, RTK typically appears as a bulky, solid, and relatively well-circumscribed lesion. The histiogenesis remains controversial, the tumor may not even be renal-specific since morphologically indistinguishable rhabdoid tumors occur in many other sites (e.g. pelvis, soft tissue, bladder) and deletion of the hSNF5/INI1 gene on chromosome 22 has been found in all these tumors.[7] Light-microscopic and ultrastuctural features have been defined.The tumor behavior is extremely aggressive and clinical management (triple chemotherapy) has not proven successful. So far, male sex and high tumor stage are the only identified unfavorable prognosti indicators. Metastases occur most frequently in the lung (70%) and most patients with relapse die from tumor progression (NWTS 96%). The reported survival rate at 3 years is less than 20%. Congenital Mesoblastic Nephroma Microscopically CMN consists of monomorphic spindle-shaped cells, resembling fibroblasts with scant interstitial collagen. Two morphological subtypes are distinguished: the classical or leiomyomatous type and the atypical or cellular type. Mixed forms have also been described. In a series of 51 cases, 50 patients survived and only one patient experienced local recurrence.[33] Despite this excellent prognosis, local recurrence and even tumor-related death have been described and were always related to the cellular (atypical) form or to the mixed form, particularly in patients aged more than 3 months and in those cases where surgical removal was not complete. Cytogenetic studies have reported common trisomies in cellular CMN, particularly of chromosome 11 and t (12; 15) (p13; q25)-associated ETV6-NTRK3 gene fusions.[34] Total surgical excision independent of histological type without further therapy is recommended for most patients as the treatment of choice. Tumor rupture and difficulties in achieving clear surgical margins have been frequently reported but did not affect the excellent prognosis. Intrarenal neuroblastoma and intrarenal teratoma While sacrococcygeal teratomas can contain elements of Wilms tumors and Wilms tumors have been found to produce Alpha-fetoprotein, few cases of intrarenal teratomas have also been described.[36], [37] The diagnosis depends on histological examination. Teratoid Wilms tumor is defined as an unusual variant of nephroblastoma, in which there is a significant diversity of cell types and tissues along with areas of classic nephroblastoma. After complete resection, the prognosis should be excellent provided the tumor does not contain yolk sac elements. Challenges faced in developing countries 1. Poverty2. Ignorance 3. Malnutrition 4. Huge tumors 5. Stage 3-5 comprising 65% cases 6. Noncompliance with schedule 7. Limited facilities for advanced surgery and supportive services 8. Huge population with large number of cases. We follow NWTS V in 1. Staging2. Initial surgical management in stage 1 and 2 3. Neo- adjuvant chemotherapy in unresectable tumors and 4. Chemotherapy schedules. However, we differ in the management strategies as follows - 1. We do not consider laparotomy and biopsy mandatory for preliminary staging 2. FNAC is considered reliable in expert hands. Immunohistochemistry is done for cases with diagnostic dilemmas to rule out other round cell tumors. 3. We rely on clinical examination and radiology for deciding resectability based on lateral mobility in a calmed child. 4. Try and shrink very huge tumors with chemotherapy before attempting resection even though there is no evidence of stage 3 on imaging but clinically there is restricted mobility. 5. Avoid radiotherapy in bilateral Wilms′ tumor 6. Gerota′s fascia is not opened for contralateral exploration during surgery for unilateral Wilms tumor. However, every care is taken to exclude synchronous tumor and nephrogenic rests using advanced and detailed imaging preoperatively and a thorough clinical palpation is performed during surgery. A strict follow up is done to detect any metachronous tumor. Future Recent advances in understanding the molecular biology of the tumorigenesis of Wilms′ tumor have provided significant implications for the clinical management. Thus, both large study groups currently aim to intensify treatment for patients with poor prognosticators while reducing therapy and subsequent long-term complications, for those with favorable prognostic features. Parenchymal sparing renal surgery for patients with small unilateral Wilms′ tumor remains controversial. Treatment of children with Wilms′tumor should certainly involve a team of specialized pediatric surgeons, oncologists, radiologists, pathologists, and radiotherapists. References
Copyright 2005 - Journal of Indian Association of Pediatric Surgeons |
|